XML 33 R15.htm IDEA: XBRL DOCUMENT

Stockholders’ Equity

12 Months Ended

Dec. 31, 2024

Stockholders’ Equity [Abstract]

Stockholders’ equity

8. Stockholders’ Equity

Increase of authorized shares

On June 26, 2023, at our combined 2022 and 2023 Annual Meeting, our stockholders approved an amendment to our Amended and Restated Articles of Incorporation to increase the number of authorized shares of Common Stock from 12 million shares to 32 million shares.

Warrants

As of December 31, 2024, the following table summarizes the status of our outstanding and exercisable warrants and related transactions since December 31, 2022 (in thousands, except weighted average exercise price and weighted average remaining contractual life data):

		Warrants outstanding and exercisable
		Warrants				Weighted Average Exercise Price				Aggregate Intrinsic Value				Weighted Average Remaining Contractual Life (in Years)
Balance, December 31, 2022			536			$	13.10				2,427				9.3
Exercised			(435	)			0.01				(2,720	)
Expired			(2	)			0.89
Balance, December 31, 2023			99				66.61				1,793				6.5
Expired			(1	)			281.50				—				—
Balance, December 31, 2024			98			$	63.33			$	—				5.6

Share-based compensation payment plans

As of December 31, 2024, 56,530 shares of common stock were subject to outstanding awards under our share-based payment award plans and inducement grants (calculated using the base number of PSUs that may vest). As of December 31, 2024, 410,719 shares of common stock were available for future grants of share-based payment awards under the TherapeuticsMD, Inc. 2019 Stock Incentive Plan.

The following table summarizes the status of our outstanding and exercisable options and related transactions since December 31, 2022 (in thousands, except weighed average exercise price and weighted average remaining contractual life data):

		Outstanding																Exercisable
		Options Awards				Weighted Average Exercise Price				Aggregate Intrinsic Value				Weighted Average Remaining Contractual Life (in Years)				Options Awards				Weighted Average Exercise Price				Aggregate Intrinsic Value				Weighted Average Remaining Contractual Life (in Years)
As of December 31, 2022			172			$	228.28				—				3.6				170				229.43			$	—				3.6
Expired			(100	)			206.15				—				—				(98	)			—				—				—
As of December 31, 2023			72				258.55				—				3.0				72				258.46				—				3.0
Expired			(15	)			217				—				—				(15	)			—				—				—
As of December 31, 2024			57			$	270.33			$	—				2.8				57				270.20			$	—				2.8

The following table summarizes the status of our RSUs and related transactions (in thousands, except weighed average grant date fair value):

		RSUs awards outstanding
		RSUs				Weighted Average Grant Date Fair Value				Aggregate Intrinsic Value
Balance, as of December 31, 2022			57			$	14.57			$	318.63
Granted			163				4.82				—
Vested			(180	)			6.83				—
Balance, as of December 31, 2023			40				9.67				89.60
Vested			(38	)			9.11				—
Balance, as of December 31, 2024			2			$	21.78			$	1.49

The following table summarizes the status of our PSUs and related transactions for each for the following years (in thousands, except weighed average grant date fair value):

		PSUs				Weighted Average Grant Date Fair Value				Aggregate Intrinsic Value
Unvested, as of December 31, 2022			19			$	52.15			$	107.55
Vested			(7	)			56.05				(10.72	)
Unvested, as of December 31, 2023			12				49.36				27.3
Vested			(7	)			60.50				16.16
Balance, as of December 31, 2024			5			$	34.50			$	4.47

Share-based payment compensation cost

Share-based payment compensation expense for PSUs is based on 100% vesting which was a part of the termination benefits for all employees who were terminated in 2022. We recorded share-based payment award compensation costs related to previously issued options, RSU and PSUs, as well as shares of common stock issued under our employee stock purchase plan (“ESPP”) totaling $264.1 thousand for 2024 and $1,271.2 thousand for 2023.

As of December 31, 2024, we had $23.9 thousand of unrecognized share-based payment award compensation cost related to unvested options, RSUs and PSUs as well as shares issuable under our ESPP, which may be adjusted for future changes in forfeitures and is included as additional paid-in capital in the accompanying consolidated balance sheets. No tax benefit was realized due to a continued pattern of net losses.

The unrecognized compensation cost as of December 31, 2024 of $23.9 thousand is expected to be recognized as share-based payment award compensation over a weighted average period of 0.2 years.